BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36050547)

  • 1. Identification of a Multi-Component Formulation for Intestinal Delivery of a GLP-1/Glucagon Co-agonist Peptide.
    Tran H; Patel PJ; Aburub A; Sperry A; Estwick S; ElSayed MEH; -Mannan AD
    Pharm Res; 2022 Oct; 39(10):2555-2567. PubMed ID: 36050547
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Tran H; Aihara E; Mohammed FA; Qu H; Riley A; Su Y; Lai X; Huang S; Aburub A; Chen JJH; Vitale OH; Lao Y; Estwick S; Qi Z; ElSayed MEH
    Mol Pharm; 2023 Feb; 20(2):929-941. PubMed ID: 36592951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and evaluation of C10 and SNAC erodible tablets for gastric delivery of a GIP/GLP1 peptide in monkeys.
    Tran H; Dogra M; Huang S; Aihara E; ElSayed M; Aburub A
    Int J Pharm; 2024 Jan; 650():123680. PubMed ID: 38070657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the physicochemical interactions between exenatide and two intestinal permeation enhancers: Sodium caprate (C
    Twarog C; Fattal E; Noiray M; Illel B; Brayden DJ; Taverna M; Hillaireau H
    Int J Pharm; 2022 Oct; 626():122131. PubMed ID: 36028084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and Development of a New Glucagon-Like Peptide-1 Receptor Agonist to Obtain High Oral Bioavailability.
    Chen H; Lu Y; Shi S; Zhang Q; Cao X; Sun L; An D; Zhang X; Kong X; Liu J
    Pharm Res; 2022 Aug; 39(8):1891-1906. PubMed ID: 35698011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enteroendocrine-derived glucagon-like peptide-2 controls intestinal amino acid transport.
    Lee J; Koehler J; Yusta B; Bahrami J; Matthews D; Rafii M; Pencharz PB; Drucker DJ
    Mol Metab; 2017 Mar; 6(3):245-255. PubMed ID: 28271031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation in pig of an intestinal administration device for oral peptide delivery.
    Berg S; Uggla T; Antonsson M; Nunes SF; Englund M; Rosengren L; Fahraj M; Wu X; Govender R; Söderberg M; Janzén D; Van Zuydam N; Hugerth A; Larsson A; Abrahmsén-Alami S; Abrahamsson B; Davies N; Bergström CAS
    J Control Release; 2023 Jan; 353():792-801. PubMed ID: 36493948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of the intestinal permeation enhancers, SNAC and sodium caprate (C
    Twarog C; McCartney F; Harrison SM; Illel B; Fattal E; Brayden DJ
    Eur J Pharm Sci; 2021 Mar; 158():105685. PubMed ID: 33359131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.
    Hargrove DM; Alagarsamy S; Croston G; Laporte R; Qi S; Srinivasan K; Sueiras-Diaz J; Wiśniewski K; Hartwig J; Lu M; Posch AP; Wiśniewska H; Schteingart CD; Rivière PJ; Dimitriadou V
    J Pharmacol Exp Ther; 2020 May; 373(2):193-203. PubMed ID: 32075870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
    Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
    Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.
    Hansen L; Deacon CF; Orskov C; Holst JJ
    Endocrinology; 1999 Nov; 140(11):5356-63. PubMed ID: 10537167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological actions and therapeutic potential of the glucagon-like peptides.
    Drucker DJ
    Gastroenterology; 2002 Feb; 122(2):531-44. PubMed ID: 11832466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas.
    Orskov C; Holst JJ; Knuhtsen S; Baldissera FG; Poulsen SS; Nielsen OV
    Endocrinology; 1986 Oct; 119(4):1467-75. PubMed ID: 3530719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist.
    Buckley ST; Bækdal TA; Vegge A; Maarbjerg SJ; Pyke C; Ahnfelt-Rønne J; Madsen KG; Schéele SG; Alanentalo T; Kirk RK; Pedersen BL; Skyggebjerg RB; Benie AJ; Strauss HM; Wahlund PO; Bjerregaard S; Farkas E; Fekete C; Søndergaard FL; Borregaard J; Hartoft-Nielsen ML; Knudsen LB
    Sci Transl Med; 2018 Nov; 10(467):. PubMed ID: 30429357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of salmon calcitonin (sCT) enteric-coated capsule for enhanced absorption and GI tolerability in rats.
    Wu L; Zhang G; Lu Q; Sun Q; Wang M; Li N; Gao Z; Sun Y; Li T; Han D; Yu X; Wang L; Sun W; Zhao D; Wu Y; Lu Y; Chen X
    Drug Dev Ind Pharm; 2010 Mar; 36(3):362-70. PubMed ID: 19719396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide 2 function in domestic animals.
    Burrin DG; Stoll B; Guan X
    Domest Anim Endocrinol; 2003 Mar; 24(2):103-22. PubMed ID: 12586312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
    Liu L; Liu J; Wong WT; Tian XY; Lau CW; Wang YX; Xu G; Pu Y; Zhu Z; Xu A; Lam KS; Chen ZY; Ng CF; Yao X; Huang Y
    Hypertension; 2012 Sep; 60(3):833-41. PubMed ID: 22868389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A silica-based pH-sensitive nanomatrix system improves the oral absorption and efficacy of incretin hormone glucagon-like peptide-1.
    Qu W; Li Y; Hovgaard L; Li S; Dai W; Wang J; Zhang X; Zhang Q
    Int J Nanomedicine; 2012; 7():4983-94. PubMed ID: 23028226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo preclinical evaluation of a minisphere emulsion-based formulation (SmPill®) of salmon calcitonin.
    Aguirre TA; Rosa M; Coulter IS; Brayden DJ
    Eur J Pharm Sci; 2015 Nov; 79():102-11. PubMed ID: 26349051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
    Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.